by Amy Adams on August 30, 2011 at 1:19PM | comments
A few weeks ago CIRM grantee at UC Davis Paul Knoepfler wrote a blog entry distinguishing hype from hope in the stem cell research field. This is no small task. The hype in this field is incredible (as evidence, see all too many headlines on the topic). But then, so is the hope. CIRM was voted into existence by the 59% of Californians who had high hopes for therapies coming out of stem cell research.
by Amy Adams on August 11, 2011 at 12:47PM | comments
Every once in a while CIRM grantee Paul Knoepfler at UC Davis posts an update on his blog about what he considers to be the big ticket question in research using reprogrammed adult cells, known as iPS cells. This time, he's posted five questions for the upcoming year.
CIRM grantee Paul Knoepfler at UC Davis has been blogging about stem cell science for a while now. He recently expanded his outreach to include a regular podcast. It's worth checking out. He's listing the most recent podcast at the top of his main blog page: http://www.ipscell.com/ .
by Amy Adams on June 13, 2011 at 11:13AM | comments
Last week The Scientist carried a story addressing a topic near and dear to the heart of anyone trying to develop a therapy based on transplanting stem cells, whether they are embryonic, adult, or iPS cells: Where do the cells go once they are transplanted?
by Amy Adams on June 8, 2011 at 12:50PM | comments
Blood has been among the most sought after and hardest to achieve tissue that CIRM grantees are attempting to derive from embryonic stem cells. It's an obvious target. The medical system needs a constant influx of blood, which comes entirely from volunteer donors. Creating that blood in an unlimited supply from human embryonic stem cells would significantly ease concerns about blood shortages at hospitals.
by Amy Adams on November 10, 2010 at 10:51AM | comments
A story by Nick Wade in Monday's New York Times rubbed some scientists the wrong way - and I must admit the piece was not too popular around CIRM headquarters.
Wade equated research funding with picking stocks. His idea is that a broad portfolio is bound to include some winners (he attributes this approach to the NIH and NSF) whereas attempts to only buy the big winners can produce a risky portfolio (an approach he attributes to CIRM).
by Amy Adams on September 17, 2010 at 12:12PM | comments
Thanks to UC Davis stem cell scientist and CIRM grantee Paul Knoepfler for ferreting out the three judges who will preside over the September 27 D.C. Circuit Court hearing regarding the August 23 injunction on federal funding for human embryonic stem cell research.
In his blog entry, Knoepfler writes that of the three judges one is a Clinton appointee and two were appointed by Bush Jr.